<DOC>
	<DOCNO>NCT02912949</DOCNO>
	<brief_summary>This Phase I/II , open-label , multi-center , multi-national , dose escalation , single agent study ass safety , tolerability , PK , PD , immunogenicity anti-tumor activity MCLA-128</brief_summary>
	<brief_title>A Study MCLA-128 Patients With Solid Tumors</brief_title>
	<detailed_description>Study Design : This open label ( participant know identity study drug ) , multicenter ( one study site ) , first-in-human study consist 2 part . Part 1 dose escalation Part 2 dose expansion cohort . Part 1 complete . Part 2 patient population interest receive RP2D determine Part 1 : - relapsed/refractory HER2-amplified breast cancer ( Group A ) ; - advanced/metastatic epithelial ovarian cancer ( Group C ) ; - advanced/metastatic HER2-amplified gastric cancer esophageal-gastric junction adenocarcinoma ( Group D ) ; . - advanced/metastatic endometrial cancer ( Group E ) ; - advanced/metastatic recur HER2 express non small cell lung cancer ( Group F ) ; Part 2 characterize safety tolerability select dose level MCLA-128 , well assessment CBR , define proportion patient CR , PR durable SD ( SD least 12 week duration ) . The study consist 3 period : Screening period ( 28 day prior first dose study drug ) ; Treatment period ( first dose study drug last dose study drug treatment cycle 21 day ) ; Follow Up period ( 30 day last dose quarterly check survival data 2 year ) . Participants ' safety monitor throughout study . Number Sites : Up 10 site estimate involved Parts 1 2 study . Additional site may add ensure acceptable enrollment rate replace non-enrolling/withdrawn site .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>At least one measurable lesion accord RECIST v1.1 ; Performance status ECOG 0 1 ; Estimated life expectancy least 12 week ; Toxicities incur result previous anticancer therapy resolve ≤Grade 1 ; At least 4week interval since last received radiotherapy ; Recovery major surgery ; Absolute neutrophil count ≥1.5 x 109/L without colony stimulate factor support ; Platelets ≥100 x 109/L ; Hemoglobin ≥9 g/dL ≥2.2 mmol/L ( transfusion dependent ) ; Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) ; AST ( SGOT ) ≤2.5 x ULN ; ALT ( SGPT ) ≤2.5 x ULN ; ≤5 x ULN patient advance solid tumor liver metastasis ; patient confirm bony metastasis permit study isolated elevation ALP &gt; 5 x ULN ; Serum creatinine ≤1.5 x ULN estimate glomerular filtration rate ( GFR ) &gt; 50 mL/min coagulation function ( INR , aPTT ≤1.5 x ULN , unless therapeutic anticoagulant ) ; Urine protein ≤ 2+ ( measure dipstick ) ≤100 mg/24 hour urine Able provide tumor biopsy sample ( preferably fresh else archival ) ; archival : take within 2 year screen ; Not pregnant nursing Fertile patient must use effective contraception 6 month completion study therapy ; Patient metastatic cancer disease progression receive treatment available therapy know convey clinical benefit Specific Inclusion Criteria Part 2 ( Group A ) breast cancer ( BC ) : Histologicallyconfirmed document advanced / metastatic BC , relapsed/refractory least 2 prior HER2 direct regimen BC ; Confirmed HER2 amplification base historical pathology report analysis baseline fresh/archival tumor sample . Specific Inclusion Criteria Part 2 ( Group C ) ovarian cancer ( OC ) : Histologicallyconfirmed documented advanced/metastatic epithelial OC curative therapy available ; Prior therapy include available standard therapy least 1 platinum base chemotherapy . Specific Inclusion Criteria Part 2 ( Group D ) gastric esophagealgastric junction cancer ( GC GEC ) : Histologicallyconfirmed documented advanced/metastatic GC GEC ; Prior chemotherapy include platinum fluoropyrimidine base treatment trastuzumab Confirmed HER2 amplification base historical pathology report analysis fresh/archival tumor sample . Specific Inclusion Criteria Part 2 ( Group E ) endometrial cancer ( EC ) : Histologicallyconfirmed documented advanced/metastatic EC curative therapy available ; Prior therapy include available standard therapy least 1 prior chemotherapy . Specific Inclusion Criteria Part 2 ( Group F ) Non small cell lung cancer ( NSCLC ) : Histologically cytologically document diagnosis Stage IIIB amenable radical treatment Stage IV NSCLC ; pathological characterization nonsquamous squamous histological subtype adenocarcinoma subtype classification ; Confirmed HER2 expression ( IHC ) base historical pathology report analysis baseline ( fresh archival ) tumor sample ; Prior treatment include available standard therapy least one regimen platinumbased chemotherapy locally advanced/metastatic setting/recurrent NSCLC document disease progression investigator assessment ; Patients ALK fusion oncogene document disease progression intolerance firstline ALK Tyrosine Kinase Inhibitor ( TKI ) approve treatment ALK fusion oncogene NSCLC ; Patients know mutation EGFR gene must document disease progression intolerance EGFR TKI approve treatment EGFRmutant NSCLC . Pregnant lactating ; Presence active infection unexplained fever ; Known hypersensitivity component MCLA128 ; Known HIV , Hepatitis B Hepatitis C ; patient treat Hepatitis C undetectable viral load eligible Any untreated central nervous system lesion Patients leptomeningeal metastasis Presence congestive heart failure Left Ventricular Ejection Fraction &lt; 50 % history significant cardiac disease , unstable angina , myocardial infarction ventricular arrhythmia require medication . Previous concurrent malignancy ( exclude nonbasal cell carcinoma skin carcinoma situ uterine cervix ) unless tumor treat curative intent 2 year prior study entry ; Presence medical psychological condition deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result . Prior antitumor therapy within 28 day prior first schedule day dose MCLA128 unless time interval equal least five halflives investigational agent pass ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Bispecific Antibody IgG1 , HER2 , HER3</keyword>
	<keyword>First-in-human</keyword>
	<keyword>MCLA-128</keyword>
	<keyword>Antibodies , Bispecific</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>Cytokines</keyword>
</DOC>